Kadmon to Present at the 15th Annual BIO Investor Forum

NEW YORK–(BUSINESS WIRE)– Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal,
M.D., President and Chief Executive Officer, will present an overview of
the Company and its clinical programs at the 15th Annual BIO Investor
Forum on Tuesday, October 18 at 10:00 a.m. PT in San Francisco,
California.

A live audio webcast of the presentation may be accessed on the
Investors section of the Kadmon website at www.kadmon.com.
A replay of the webcast will be available for 90 days.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company
focused on developing innovative products for significant unmet medical
needs. We have a diversified product pipeline in autoimmune and fibrotic
diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements
may be preceded by the words “may,” “will,” “should,” “expects,”
“plans,” “anticipates,” “could,” “intends,” “targets,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. More detailed information about Kadmon and
the risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s filings with the U.S.
Securities and Exchange Commission (SEC), including the Company’s
prospectus filed pursuant to Rule 424(b) under the Securities Act of
1933, as amended, with the SEC on July 27, 2016. Investors and security
holders are urged to read these documents free of charge on the SEC’s
web site at www.sec.gov.
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161017005168/en/